Literature DB >> 3619417

Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

S S Crosby, W A Edwards, C Brennan, E P Dellinger, L A Bauer.   

Abstract

A study was performed with 10 hospitalized patients to determine the percentage of an aminoglycoside dose (tobramycin or gentamicin) that is absorbed systemically after being instilled into the endotracheal tube at steady state. All patients were on respirators, had indwelling urinary catheters, and had creatinine clearances estimated to be greater than or equal to 40 ml/min. Tobramycin or gentamicin (40 mg) was instilled every 4 h directly into the endotracheal tube. Nine patients also received systemically a different aminoglycoside from that administered through the endotracheal tube. Urine was collected over a 4-h dosing interval at steady state (after at least 5 doses of the drug). The amount of aminoglycoside excreted over the 4-h interval was measured and expressed as percentage of the dose administered over that period. The range of percentage of dose absorbed was 1.5 to 34%, with a mean of 16.7 +/- 11.4% standard deviation and a median of 16.5%. The coefficient of variation was 68%. Levels of the endotracheally administered aminoglycoside in serum were measured, and all were less than 1.0 microgram/ml. While a large degree of variability in absorption was observed in this study, significant amounts of aminoglycosides could be absorbed in some patients. However, levels apparently did not accumulate in sera of patients with adequate renal function, and an empirical dosage reduction in intravenous aminoglycoside should not be necessary with the addition of endotracheally instilled aminoglycoside in patients with creatinine clearances greater than 40 ml/min.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619417      PMCID: PMC284198          DOI: 10.1128/AAC.31.6.850

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Combined topical pulmonary and systemic gentamicin: The question of safety.

Authors:  K B Lake; J J Dyke; J A Rumsfeld
Journal:  Chest       Date:  1975-07       Impact factor: 9.410

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  The concentration of tobramycin in bronchial secretions.

Authors:  M R Alexander; E M Berglund; J E Kasik; A Fox; W M Chinn
Journal:  Chest       Date:  1979-06       Impact factor: 9.410

4.  Renal clearance and tissue accumulation of gentamicin.

Authors:  J J Schentag; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

5.  Therapeutic implications of interaction of gentamicin and penicillins.

Authors:  P Noone; J R Pattison
Journal:  Lancet       Date:  1971-09-11       Impact factor: 79.321

6.  Bronchial secretion concentrations of tobramycin.

Authors:  M R Alexander; J Schoell; G Hicklin; J E Kasik; D Coleman
Journal:  Am Rev Respir Dis       Date:  1982-02

7.  Endotracheal gentamicin in bronchial infections in patients with tracheostomy.

Authors:  J Klastersky; C Geuning; E Mouawad; D Daneau
Journal:  Chest       Date:  1972-02       Impact factor: 9.410

8.  Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration.

Authors:  W Odio; E Van Laer; J Klastersky
Journal:  J Clin Pharmacol       Date:  1975-07       Impact factor: 3.126

9.  Endotracheally administered antibiotics for gram-negative bronchopneumonia.

Authors:  J Klastersky; F Carpentier-Meunier; L Kahan-Coppens; J P Thys
Journal:  Chest       Date:  1979-05       Impact factor: 9.410

10.  Aminoglycoside inactivation by penicillins and cephalosporins and its impact on drug-level monitoring.

Authors:  R J Tindula; P J Ambrose; A F Harralson
Journal:  Drug Intell Clin Pharm       Date:  1983-12
View more
  2 in total

1.  Elevated tobramycin concentrations following endotracheal administration in a premature infant.

Authors:  Amanda Howard-Thompson; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2008-04

2.  Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.

Authors:  D J Touw; F A Jacobs; R W Brimicombe; H G Heijerman; W Bakker; D D Briemer
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.